April 21, 2016 — A new study by University of California Los Angeles (UCLA) researchers found a commonly used chemotherapy drug shows no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the specific use of anthracycline-based therapies can lead to decreased neuropsychological functioning and cognitive difficulties, such as memory loss.